Gel-forming Systems for Adhesion Prevention

Award Information
Agency:
Department of Health and Human Services
Amount:
$100,000.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2001
Phase:
Phase I
Agency Tracking Number:
1R43GM063291-01
Solicitation Topic Code:
N/A
Small Business Information
POLY-MED, INC.
6309 HWY 187, ANDERSON, SC, 29625
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 SHALABY SHALABY
 () -
Business Contact
Phone: (864) 646-8544
Email: SHALABY@POLY-MED.COM
Research Institution
N/A
Abstract
DESCRIPTION (Verbatim from the Applicant's Abstract): Adhesion formation after abdominal surgery is a significant cause of post-operative morbidity. In gynecological surgery, adhesions can lead to infertility, chronic pain, and obstructive disorder. Numerous adhesion prevention adjuvant have been investigated, most of which are based on a pharmacological agents or protective barriers. However, no systematic studies have been conducted to determine the combined effect of a transient barrier and pharmacological agent using a local, controlled release system. This provided an incentive to conduct comparative studies on controlled release systems based on unique transient barriers containing previously tested pharmacological agents or potentially effective ones. Phase I objective is to determine the feasibility of using gel-forming, hyaluronic acid/calcium acetate aqueous solution and no aqueous absorbable liquid co polyester as transient barrier matrices to control release of pharmacologically active agents for preventing post-surgical adhesion. Phase I plans entail (1) identifying and synthesizing fast absorbing liquid gel-forming co-polyesters; (2) preparing and conducting comparative rheological studies on hyaluronic acid Ca acetate (HA/CaAc) and liquid copolyesters as candidate matrices for controlled drug release, (3) formulating, the selected (HA/CaAc) and liquid copolyesters with selected pharmacological agents; (4) validating, and conducting a pilot study on three rat models for evaluation of three types of post-surgical adhesion, (5) conducting' the main study and using the results to identify two promising formulations for a Phase II study This will entail (1) completing a comprehensive in vivo studies using three animal species; (2) selecting one final system and completing pertinent development and scale-up studies; and (3) initiating the safety study. PROPOSED COMMERCIAL APPLICATION: Successful completion of Phase I study will provide the bases for pursuing a Phase II study and eventual development and marketing of a unique, highly effective system for managing key post-surgical complications associated with several procedures. This will not only benefit patients, but also reduce the cost of healthcare.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government